Jbpos0101 (DrugBank: JBPOS0101)
1 disease告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
145 | ウエスト症候群 | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03976076 (ClinicalTrials.gov) | March 1, 2019 | 31/5/2019 | A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients | A Phase 2 Study to Assess the Safety, Tolerability, Exploratory Efficacy, and Pharmacokinetics of Orally Administered JBPOS0101 for Refractory Infantile Spasms Patients | Refractory Infantile Spasms | Drug: JBPOS0101 | Bio-Pharm Solutions Co., Ltd. | NULL | Recruiting | 6 Months | 24 Months | All | 35 | Phase 2 | United States |